

## TEST: INBORN ERRORS OF METABOLISM TO DETECT:

- Congenital hypothyroidism
- Congenital adrenal hyperplasia
- Aminoacidopathies
- Organic acidemias (or acidurias) including isovaleric acidemia and methylcrotonyl-CoA-carboxylase deficiency
- Disorders of fatty acid oxidation including medium-chain-acyl-CoA dehydrogenase (MCAD) deficiency
- Biotinidase deficiency
- Galactosemia

### CONGENITAL HYPOTHYROIDISM

Congenital hypothyroidism occurs sporadically, with an incidence of one in about 4000 newborns; some familial cases have been described. Dysgenesis or ectopic position of the thyroid gland are common causes of the disease. Treatment is very easily achieved by giving the necessary dose of thyroxine.

### CONGENITAL ADRENAL HYPERPLASIA

A defect in the biosynthesis of cortisol leads to hyperplasia of the adrenal glands, resulting in an over-production of androgens and in a deficiency in mineralocorticoids. An acute salt wasting crisis which is lethal in many cases can result. Measurement of 17-Hydroxyprogesterone in term babies can detect this inborn error of steroid metabolism.

### AMINOACIDOPATHIES

Disorders of amino acid metabolism are caused by inherited enzymatic defects in the relevant metabolic pathways. Phenylketonuria (PKU) is the most important one. Without early treatment it leads to severe mental retardation. During the first days and weeks of life these babies show no signs of disease. Diagnosis by clinical means alone is therefore insufficient. Citrullinemia is a rare disorder of the urea cycle, resulting from argininosuccinate synthetase deficiency. In some cases, it presents as an overwhelming disease on the first days of life. In some other cases late onset of symptoms is observed. Neonatal screening will allow early diagnosis and treatment to prevent metabolic crisis and severe neurological defects at least in late onset cases. By measuring a spectrum of amino acid concentrations in blood there is a chance to also detect very rare diseases like maple syrup urine disease or a certain fraction of homocystinuria.

### ORGANIC ACIDEMIAS (OR ACIDURIAS)

Organic acidemias present as acute or more chronic disorders, neonates presenting with seizures, metabolic acidosis or feeding problems and lethargy. The mainstay of longterm treatment consists of reduced intake of branched chain aminoacids which lead to production of organic acids. Although it is not possible to detect all known organic acidemias during the first days of life, there is a good chance to detect isovaleric acidemia and methylcrotonyl-CoA-carboxylase deficiency before clinical disease becomes obvious.

### DISORDERS OF FATTY ACID OXIDATION

Generation of energy from fat is necessary in situations of high metabolic turnover or when other sources of energy are failing which happens in fasting periods or during infectious diseases. The body uses fat mainly by stepwise degradation of long chain fatty acids to short chains via the so called  $\beta$ -oxidation pathway, located in mitochondria. A large number of enzymes are involved, many of which may show inherited functional defects thus causing specific diseases. Not all of them produce detectable biochemical abnormalities, but some can be discovered rather easily by tandem mass spectrometry during the first days of life. The incidence of disorders of  $\beta$ -oxidation shows a great variability among populations and races. The defect of enzymatic degradation of medium chain fatty acids (MCAD-defect) however is the most important one. Although some of the children carrying this defect will never develop a clinical disease, others may die after acute metabolic decompensation. Therapy does not require any aggressive treatment. However, it is necessary to ensure sufficient carbohydrate intake at all times, especially at times of metabolic stress.

### BIOTINIDASE DEFICIENCY

Biotin, also called Vitamin H, is the functional group of four important enzymes. If biotinidase is lacking sufficient activity the body loses biotin via urine in form of biocytine; in addition, not all of the biotin contained in food can be absorbed. The resulting disease, which can be prevented easily by oral application of free biotin, is called late onset multiple carboxylase deficiency. The incidence is rather low. However, clinical diagnosis is very difficult though treatment is easily achieved and prevents severe (neurological) symptoms. Therefore, many screening laboratories have added the test to their programs.

### GALACTOSEMIA

Three different forms of galactosemia are known. The incidence is about one in 40.000 newborns. In galactokinase deficiency dietary treatment is preventing cataracts of the eye lens, however, classical galactosemia is more difficult to manage. Without diagnosis, affected children may die from liver failure. They can be saved by withholding lactose in the diet. For longterm prognosis however one has to keep in mind that some of the sequelae will develop irrespective of the quality of therapy.

### EXAMPLE REPORT TEXT FOR INBORN ERRORS OF METABOLISM SCREEN:

Analyte or procedure	Results	Normal range	Unit
Visual Quality of blood card	good	----	
Thyroid stim. hormone (TSH)	unremarkable	<15	$\mu$ U/ml
17-OH-Progesterone	unremarkable	<30	nmol/l
Galactose (GAL, GAL-1-P)	unremarkable	<20	mg/dl
Biotinidase	unremarkable	>25	% activity
Phenylalanine	unremarkable	<3.0	mg/dl
Spectrum of 7 amino acids	unremarkable	----	
Spectrum of 32 acylcarnitines	unremarkable	----	

Comments: No pathologic results obtained

The analysis did not give any indication of

- Congenital hypothyroidism (TSH)
- Congenital adrenal hyperplasia (17-OH-progesterone)
- Galactosemia (GAL, GAL-1-P)
- profound biotinidase deficiency (Biotinidase)
- phenylketonuria, maple syrup urine disease or citrullinemia (amino acids: Phe, Tyr, Leu/Ileu, Val, Ala, Cit, Orn)
- propionic-, isovaleric-, methylmalonic- or glutaric acidemia, methylcrotonyl-CoA-carboxylase deficiency or MCAD deficiency (acylcarnitines: carnitine and 32 acylcarnitines, tandem mass spectrometry)

It is important to bear in mind that neonatal screening will not reveal inborn errors of metabolism or endocrinopathies when biological processes or therapy keep analytes in vivo in a normal range. An exact medical examination is mandatory if any symptoms of such diseases occur. The results are valid only when the infant was at least 36 hours old and has not received any blood transfusion prior to blood collection. Please note that the cut-off for 17-OH- progesterone depends on gestational age and/or birth weight.

## NEWBORN SCREENING: TEST LIST

### DISORDERS OF GALACTOSE METABOLISM:

1. Galactose 1-phosphate-uridylyltransferase deficiency\* (Gal.Gal-1P)
2. Galaktokinase deficiency\* (Gal.Gal-1P)
3. UPD-galactose-4-epimerase deficiency\* (Gal.Gal-1P)

### DISORDERS OF AMINO ACID METABOLISM

#### (TANDEM MASS SPECTROMETRY/ TMS: AMINOACIDS):

4. Phenylketonuria/Hyperphenylalaninemia
5. Maple syrup urine disease (MSUD)
6. Citrullinemia
7. Argininosuccinic aciduria

### ORGANIC ACIDEMIAS (TMS: ACYLCARNITINES)

8. Propionic acidemia
9. Methylmalonic acidemia
10. Isovaleric acidemia
11. 3-Methylcrotonyl-CoA-carboxylase deficiency
12. Multiple carboxylase deficiency
13. Glutaric acidemia type 1

### DISORDERS OF FATTY ACID OXIDATION

#### (TMS: ACYLCARNITINES)

14. Short-chain acyl-CoA dehydrogenase (SCAD) deficiency
15. Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency
16. Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency
17. Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency/trifunctional protein (TFP) deficiency
18. Multiple-acyl-CoA dehydrogenase (MAD) deficiency

### DISORDERS OF CARNITINE METABOLISM

#### (TMS: ACYLCARNITINES)

19. Carnitine transporter deficiency
20. Carnitine palmitoyl transferase I deficiency
21. Carnitine palmitoyl transferase II deficiency
22. Carnitine translocase deficiency

### SINGLE TESTS

23. Hypothyroidism (ELISA, quantitative: TSH)
24. Congenital adrenal hyperplasia (ELISA, quantitative: 17-OH-Progesterone)
25. Biotinidase deficiency (enzyme activity)

\*rare disorders which can only be detected if sufficient lactose has been ingested

## SPECIMEN REQUIREMENT

### HOW NEONATAL SCREENING IS ACHIEVED:

#### The first step: blood collection (specimen requirement):

Blood is collected by heel prick or venous puncture, taken on the third day of life. The laboratory needs 6-7 drops of blood on a special filter card, available from Bioscientia. Each spot has to be saturated with one big drop of blood. After drying the sample in ambient air without the application of any additional heat or light this material is suitable to be sent to us.

#### The second step: providing the necessary information/patient data:

The laboratory has to be informed of name and sex of the baby. To correctly interpret the analytical results the day of birth and of blood collection as well as birth weight and gestational age must be quoted.

#### The third step: sending the sample:

It is very important that we receive the sample as quickly as possible to allow a prompt diagnosis for the immediate commencement of treatment before symptoms arise.

## CONTACT/ADDRESS

BIOSCIENTIA  
INT. SUPPORT SERVICES DEPT.  
KONRAD-ADENAUER-STR. 17  
55218 INGELHEIM  
GERMANY

Phone: ++49-6132-781-203, 224 or 165  
Fax: ++49-6132-781-236  
E-mail: [int.support@bioscientia.de](mailto:int.support@bioscientia.de)  
Website: [www.bioscientia.de](http://www.bioscientia.de)

BIOSCIENTIA REGIONAL HEADQUARTERS  
MANAGER INT. MARKETING  
MR. DAVID ISAAC  
P.O. Box 3264  
DUBAI  
UNITED ARAB EMIRATES

Phone: ++971-4-397-4948  
Fax: ++971-4-397-4129  
E-mail: [bioscien@emirates.net.ae](mailto:bioscien@emirates.net.ae)  
Website: [www.bioscientia.de](http://www.bioscientia.de)

Author: for further information on neonatal screening please contact  
Prof. Dr. med. J. Sander (e-mail: [j.sander@metabscreen.de](mailto:j.sander@metabscreen.de))  
Screening-Labor Hannover, Germany  
January 2004

A Healthcare Professional Information from **bioscientia**

**bioscientia**

INSTITUTE FOR  
LABORATORY  
ANALYSES

Konrad-Adenauer-Str. 17  
55218 Ingelheim, Germany


Phone: ++49-6132-781-203, 224 or 165

Fax: ++4 9 - 6 1 3 2 - 7 8 1 - 2 3 6


E-mail: [int.support@bioscientia.de](mailto:int.support@bioscientia.de)

Website: [www.bioscientia.de](http://www.bioscientia.de)

## NEWBORN SCREENING FOR THE EARLY DETECTION OF INBORN ERRORS OF METABOLISM



Tandem mass spectrometry: Acylcarnitines, normal pattern



Tandem mass spectrometry: Phenylketonuria (PKU)

A Healthcare Professional Information from **bioscientia**